A Partially-Blind, Randomized, Single-Dose, Placebo-Controlled Crossover Phase I Study Assessing the Effect of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of SMC021 0.8 mg in Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2008
At a glance
- Drugs Calcitonin (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 14 Oct 2008 Results have been published in BMC Clinical Pharmacology, according to an Emisphere media release.
- 19 Nov 2006 New trial record.